IDD Biotech – differentiated therapeutic MAbs

IDD biotech aims to improve the life of patients by developing differentiated therapeutic MAbs for the pharmaceutical market with a pipeline of internally discovered product candidates and strategic collaborations with research institutes and pharmaceutical companies.

IDD Biotech – differentiated therapeutic MAbs

IDD Biotech

Continue reading

Swecure – immunoregulatory disorders

Swecure is a Swedish biotechnology company developing treatments for immunoregulatory disorders, such as allergy and IBD.

Swecure – immunoregulatory disorders

swecure AB

Continue reading

Medigene – personalized immunotherapies

Medigene is a biotech company focusing on the development of personalized T-cell immunotherapies. Medigene develops highly innovative treatment platforms concentrating on haematological malignancies, cancer and autoimmune diseases.

Medigene – personalized immunotherapies

medigene Continue reading

Selvita – accelerating drug discovery

Selvita is a biotech company offering drug discovery support at every step of the process, from the early discovery phase up to preclinical research. Selvita delivers a comprehensive panel of solutions to accelerate and decrease the cost of the introduction of new drugs to the market.

Selvita – accelerating drug discovery

selvita Continue reading

TxCell – antigen-specific Type 1 Treg cells

TxCell is a biotech company developing innovative and personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for autoimmune diseases and severe chronic inflammatory diseases.

TxCell – antigen-specific Type 1 Treg cells

txcell Continue reading

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics is a biotech company developing bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders. Zenith Epigenetics aims to become a leading epigenetic company translating bromodomain biology into impactful therapies.

Zenith Epigenetics – bromodomain inhibitors

Zenith Epigenetics

Continue reading